Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

Trial Details

NCT ID
NCT07396324
Phase
PHASE2
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Iparomlimab and Tuvonralimab
  • Paclitaxel
  • Carboplatin
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged ≥18 years
  • Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer
  • Subjects with at least one evaluable lesion
  • Adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →